Last reviewed · How we verify

NCT07485309

Periareolar Excision vs Pull-Through in Gynecomastia

Completed NA Last updated 20 March 2026
What this trial tests

NA trial testing Periareolar Excision in Gynecomastia in 64 participants. Completed in 1 September 2025.

Timeline
1 September 2024
Primary endpoint
1 September 2025
1 September 2025

Quick facts

Lead sponsorKafrelsheikh University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment64
Start date1 September 2024
Primary completion1 September 2025
Estimated completion1 September 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Kafrelsheikh University

Who can join

Adults 18 to 50, male only, with Gynecomastia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective randomized controlled trial compares periareolar excision and pull-through techniques in 64 patients with Simon Grade I-IIb gynecomastia. Patients were randomized 1:1 and followed for 6 months. The primary outcome was total patient satisfaction measured using the Rasch-transformed BODY-Q Chest Module. Secondary outcomes included anthropometric measurements, recovery parameters, complication rates, and blinded aesthetic evaluation. A formal interaction analysis assessed whether surgical superiority differed according to disease severity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gynecomastia

Currently open trials in the same condition.

Other Kafrelsheikh University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07485309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing